The clinical results highlight a clear dose-response relationship, with 61% of patients receiving a 600-milligram dose achieving complete skin clearance by week 16. In contrast, none of the participants in the placebo group reached this primary endpoint. Beyond the clearance rates, the company reported that the drug remains well tolerated by patients.
In section Market Quotes
Oruka Therapeutics Stock Climbs After Psoriasis Drug Trial Success
Shares of Oruka Therapeutics surged 12% to $89.77 on Monday, extending a rally that has nearly tripled the company's market value this year. The jump follows promising week 16 data from a Phase 2b trial for ORKA-001, a treatment targeting moderate-to-severe plaque psoriasis that showed significant efficacy at higher doses.
Chief medical officer Joana Goncalves noted that the trial data reinforces the potential for ORKA-001 to become a preferred treatment option due to its safety profile and infrequent dosing schedule of once or twice per year. Backed by these findings, Oruka is preparing to engage with regulatory agencies to finalize plans for Phase 3 trials, which are slated to begin in the first half of 2025.
Comments (0)
No comments yet. Be the first!